Biotest is committed to combating the coronavirus

Activities of Biotest Group against the coronavirus

TV reports, press releases and the presentation of Biotest's research activities.

Further information

CoVIg-19 PLASMA ALLIANCE

The fight against COVID-19 begins with you.

You have recovered. Then you can save others.

We are developing a potential drug. First, we need your plasma.

Be part of this historic initiative to fight the coronavirus pandemic.

Further information

A global industry addresses global challenges related to covid-19: A PPTA initiative

Leaders of the plasma-processing industry express their appreciation and gratitude for plasma donors and their commitment to providing lifesaving plasma for patients around the world.
An initiative of the Plasma Protein Therapeutics Association.

To video

Our product range

Intensive care medicine

Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.

Further information

Haematology

For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.

Further information

Clinical immunology

Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).

Further information

Human Albumin for manufacturing and research use

Through its wide range of biological functions, its stability and high solubility, Biotest Human Serum Albumin is suitable for use as a multifunctional excipient for biotechnological, pharmaceutical and diagnostic applications. It is manufactured in a GMP compliant, state-of-the-art facility and complies with the regulatory requirements of multiple health authorities.

Further Information

Our development pipeline

	Phase 1	Phase 2	Phase 3	Approval	Launch
	IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
	IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
	CMV Hyperimmunglobulin ((CMVIG) ) - Prevention of prenatal CMV transmission
	Fibrinogen (BT524) - Congenital fibrinogen deficiency
	Fibrinogen (BT524) - Acquired fibrinogen deficiency
	Trimodulin (BT588) - Severe community acquired pneumonia
	Haemophilia A Therapeutic (HAT) - Haemophilia A

Pipeline

Careers

Passionate to help us save lives?

Further information

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Further information

Company

Biotest - Innovation in haematology, clinical immunology and intensive care medicine

Research and development

Specialist for Immune Sciences

Investor Relations

Create value for our shareholders

Patients

Biotest products save lives and offer new perspectives to chronically ill patients

Careers

Passionate to help us save lives?

Biotest is committed to combating the coronavirus

Activities of Biotest Group against the coronavirus

CoVIg-19 PLASMA ALLIANCE

The fight against COVID-19 begins with you.

You have recovered. Then you can save others.

A global industry addresses global challenges related to covid-19: A PPTA initiative

Our product range

Intensive care medicine

Haematology

Clinical immunology

Human Albumin for manufacturing and research use

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Pipeline

Press releases

Careers

Careers

Investor Relations

Investor Relations

Biotest - Innovation in haematology,
clinical immunology and intensive care medicine